Navigation Links
Protalix BioTherapeutics Announces Public Offering of Common Stock
Date:10/7/2007

nologies and products under development, the identification of lead compounds, the successful preclinical development of our products, the completion of clinical trials, the review process of the FDA, foreign regulatory bodies and other governmental regulation, and other factors described in our filings with the Securities and Exchange Commission. The statements are valid only as of the date hereof and we disclaim any obligation to update this information.

For additional information, contact Protalix BioTherapeutics at: investors@protalix.com


'/>"/>
SOURCE Protalix BioTherapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... , November 24, 2014 Senior ... honored for dynamic leadership skills, business acumen ... and medical information products and services, congratulates Diane ... Clinical Reference and Workflow, Elsevier Clinical Solutions, for being ... Watching ® Awards issue of Profiles in ...
(Date:11/22/2014)... and London (PRWEB) November 21, 2014 Two ... will explore what comes next for ALS research and how ... , After the Ice Bucket Challenge: Where Does the ... Date: Tuesday, 2 December 2014, Time: 1:30pm ET, ... , Join expert speaker Dr. Merit Cudkowicz, Julianne Dorn Professor ...
(Date:11/22/2014)... Boston, MA (PRWEB) November 21, 2014 ... and key investors will gather on December 3rd ... Boston Biotech Conferences series. GeneticRx will take place ... Harvard Medical School and will discuss the present ... gene therapy, exon skipping, and gene editing—as well ...
(Date:11/22/2014)... Frederick, MD (PRWEB) November 21, 2014 ... sample management solutions provider, has released Limfinity® version ... more installation projects of Limfinity® than ever in ... majority configuration and minority framework enhancement. Limfinity® version ... goes far above and beyond bug fixes! , ...
Breaking Biology Technology:Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 2Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 3DrugDev Webinars in December to Explore What Comes Next for ALS Research and How We Can Make Life Easier for Clinical Sites 2Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd 2RURO Announces Limfinity® version 5.1.4 2
... to high quality, practice management and reimbursement content ... available through web-based delivery platform, DALLAS-FORT ... develops products and services to help accelerate,advancements in the ... in web-based delivery of healthcare,information, have joined forces to ...
... Aton Pharma, Inc., a,global specialty pharmaceutical ... an expanded, comprehensive distribution program that ... resources, for the,dry eye medication Lacrisert(R) ... unique preservative-free, once-daily*, sustained,release prescription insert ...
... the active elements in the next generation of electronic ... nanotubes within device architectures. Most of the approaches for ... applicable to discrete devices and are not readily scalable ... nanotube-based chips. Now, this seemingly intractable problem has been ...
Cached Biology Technology:Oncology Metrics and E-Expert Reimbursement Partners Announce Joint Marketing and Product Development Agreement 2Oncology Metrics and E-Expert Reimbursement Partners Announce Joint Marketing and Product Development Agreement 3Aton Pharma Introduces Expanded Distribution of Lacrisert(R) (hydroxypropyl cellulose ophthalmic insert) at Hawaiian Eye 2Aton Pharma Introduces Expanded Distribution of Lacrisert(R) (hydroxypropyl cellulose ophthalmic insert) at Hawaiian Eye 3Nanotubes go with the flow 2
(Date:11/6/2014)... metastasis, yet progress in preventing and treating migratory ... particularly challenging to design drugs that work against ... biology at Harvard Medical School. , "Unfortunately, ... metastasized." , Gujral and colleagues have now identified ... understand how metastasis begins. Their findings may also ...
(Date:11/6/2014)... 6, 2014 - Insilico Medicine, Inc, a Baltimore-based ... age related diseases announced a research collaboration with ... Champions Oncology, Inc (OTC: CSBR). , "There are ... medicine, but Champions Oncology,s TumorGraft technology is unique ... chemotherapy regimen experimentally generating vast amounts of valuable ...
(Date:11/5/2014)... career to understanding the Earth,s climate and communicating ... deputy director and regional climatologist for the Western ... Redmond has more than three decades of experience ... data to the general public. , At its ... December 15-19, 2014 the American Geophysical Union (AGU) ...
Breaking Biology News(10 mins):Migration negation 2Migration negation 3Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2
... Duchenne muscular dystrophy (DMD) face a future of rapidly weakening ... failure before their 30th birthday. While researchers are hopeful that ... have targeted the heart of the problem as much as ... grant he received from the National Institutes of Health will ...
... of toxicity in the four hemophilia B patients enrolled to ... development at St. Jude Children,s Research Hospital and UCL (University ... This trial was designed primarily as a safety test, with ... little detectable Factor IX. The Factor IX protein helps the ...
... LLC, the image analysis and pattern recognition technology ... was awarded best performance for forensic signature verification ... Handwriting Recognition (ICFHR2010) in Kolkata, India, held November ... participants representing a total of 10 offline signature ...
Cached Biology News:New NIH grant helps MU scientist get to the heart of muscular dystrophy 2Early safety results promising for Phase I/II trial of gene therapy treatment of hemophilia B 2Parascript SignatureXpert Wins Forensic Signature Verification Competition 2
Mouse Anti-human CD11b/Mac-1alpha, clone LM2/1, Monoclonal Antibody...
Mouse monoclonal [1-N-14] to Adenovirus Type 7 hexon C11 Immunogen: Purified Adenovirus type 7 Specificity: This antibody is specific for Adenovirus type 7 hexon C11....
... The epitope is specific for Kir2.1 ... other known protein.,SPECIES REACTIVITIES: The ... bovine, porcine and guinea pig. It ... mouse (17/19 residues) and chick (15/19 ...
Request Info...
Biology Products: